 |
| Autoimmune hepatitis is a chronic inflammatory liver disease not readily treatable for 20% of patients |
Autoimmune hepatitis is a chronic inflammatory liver disease. The condition is treatable for the large majority of patients. The 20 per cent or so of patients who don’t respond well to standard medicines are treated with “salvage therapies”, but until now these have been inadequately scrutinised for their efficiency and safety, a new paper says.
Monash University researchers in the Department of Gastroenterology at The Alfred Hospital have conducted a rare, comprehensive review of salvage therapies resulting in findings that could benefit clinicians and their patients with the disease globally.
